Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03722264 · ClinicalTrials.gov registry record · NA
An Evaluation of Protective Effects of OpalSeal™ Against Early Dental Decay in Orthodontic Patients
A NA study of Cavities of Teeth, sponsored by Virginia Commonwealth University.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03722264: Completed NA study of Cavities of Teeth, sponsored by Virginia Commonwealth University.
NCT03722264 is a NA study of Cavities of Teeth that has completed, run by Virginia Commonwealth University. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03722264, a NA study of Cavities of Teeth, has completed, sponsored by Virginia Commonwealth University.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Fluoride is very effective in preventing dental decay (cavities) when applied in the form of a varnish on tooth surfaces. The purpose of this study is to verify if fluoride-releasing primer (OpalSeal) offers more protection against early dental decay (cavity) compared to conventional primer (Transbond XT) during treatment with braces.
Primary Outcome
Teeth will be subjected to microCT to assess the extent of demineralization. Loss of mineral density will be measured as depth of lesions
Conditions Studied
Interventions
- DEVICE OpalSeal
- DEVICE TransbondXT
Study Locations (1)
Virginia
- School of Dentistry, Virginia Commonwealth University - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-11-16 |
| Est. Completion | 2019-04-12 |
| Phase | NA |
What the finished NCT03722264 record still lists
NCT03722264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cavities of Teeth appearing as the primary indexed condition, and to 2 interventions - of which OpalSeal is the first listed.
NCT03722264 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT03722264 about?
NCT03722264 is a clinical study titled "An Evaluation of Protective Effects of OpalSeal™ Against Early Dental Decay in Orthodontic Patients". Fluoride is very effective in preventing dental decay (cavities) when applied in the form of a varnish on tooth surfaces. The purpose of this study is to verify if fluoride-releasing primer (OpalSeal) offers more protection against early dental decay (cavity) compared to conventional primer (Transbo...
What is the current status of trial NCT03722264?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2017-11-16. Estimated completion is 2019-04-12.
What conditions does trial NCT03722264 study?
This clinical trial studies the following conditions: Cavities of Teeth.
What interventions are being tested in trial NCT03722264?
The interventions under investigation include: OpalSeal (DEVICE), TransbondXT (DEVICE).
Who is sponsoring clinical trial NCT03722264?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03722264 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cavities of Teeth
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03722264's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI